JERSEY CITY, N.J., July 24, 2026
Organon (NYSE: OGN) presented new post hoc pooled Phase 3 data from the ADORING 1 and ADORING 2 trials showing that VTAMA® (tapinarof) cream, 1% delivered early and consistent improvements in patients with moderate to severe atopic dermatitis across pediatric age groups and adults. The findings were presented at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting in Minneapolis and mark the first age-stratified pooled Phase 3 analysis evaluating Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) and Eczema Area and Severity Index 75 (EASI75) outcomes. The analysis demonstrated that therapeutic responses with VTAMA cream emerged as early as Week 2 and continued through the 8-week treatment period, reinforcing its role as a steroid-free topical treatment for adults and children aged 2 years and older.
VTAMA Demonstrates Early Skin Clearance Across Pediatric and Adult Patients
The pooled analysis included 813 adults and children with moderate to severe atopic dermatitis who were randomized 2:1 to receive VTAMA cream or vehicle once daily for eight weeks. Patients were grouped into four age categories: 2–6 years, 7–11 years, 12–17 years, and adults aged 18 years or older, with pediatric patients representing more than 80% of the study population. Across all age groups, VTAMA cream produced clinically meaningful improvements in both vIGA-AD skin clearance and EASI75 response rates compared with vehicle. At Week 8, vIGA-AD response rates reached 56.3% versus 11.8% in children aged 2–6 years, 44.9% versus 23.8% in the 7–11-year group, 48.8% versus 13.4% among adolescents aged 12–17 years, and 38.0% versus 18.1% in adults. Similar improvements were observed for EASI75, with response rates reaching 70.2%, 53.6%, 62.2%, and 50.8%, respectively, significantly outperforming vehicle treatment across every age group.
Favorable Safety Profile Supports Broad Use in Atopic Dermatitis
The analysis also confirmed a favorable safety profile for VTAMA cream, with the most common treatment-emergent adverse events including folliculitis, headache, and nasopharyngitis, most of which were mild to moderate in severity. Importantly, treatment discontinuations due to treatment-related adverse events occurred less frequently with VTAMA cream than with vehicle, supporting its tolerability in both pediatric and adult populations. Organon highlighted that VTAMA remains the first and only steroid-free topical aryl hydrocarbon receptor (AhR) agonist approved by the U.S. FDA for treating atopic dermatitis in adults and children aged two years and older, as well as plaque psoriasis in adults. The company noted that these findings strengthen the growing clinical evidence supporting VTAMA cream as an effective long-term treatment option across a broad range of atopic dermatitis patients.
Advertisement
Organon Reinforces Commitment to Advancing Nonsteroidal Dermatology Treatments
Organon stated that the new findings reinforce its commitment to advancing innovative nonsteroidal dermatology therapies that address the needs of both pediatric and adult patients. The company emphasized that the early onset of efficacy, beginning as early as Week 2, combined with consistent improvements through Week 8, provides physicians with greater confidence when treating patients of different age groups. VTAMA cream has already received strong recommendations from the American Academy of Dermatology (AAD) for the treatment of atopic dermatitis in both children and adults. Organon believes these new analyses further establish VTAMA as a valuable treatment option capable of delivering meaningful skin clearance while avoiding the limitations associated with long-term topical steroid use.
Source: Organon press release
